Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL UNIT RECEIVES APPROVAL OF OPTIRAY X-RAY CONTRAST MEDIA IN JAPAN

 IMCERA'S MALLINCKRODT MEDICAL UNIT RECEIVES
 APPROVAL OF OPTIRAY X-RAY CONTRAST MEDIA IN JAPAN
 NORTHBROOK, Ill., March 27 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Mallinckrodt Medical unit of St. Louis has received approval for introduction of Optiray(R), a nonionic X-ray contrast medium, in Japan.
 Optiray is a low-osmolality medium used in a broad range of radiology and cardiology procedures to provide high quality diagnostic images of the organs and cardiovascular system. It offers improved safety and patient tolerance attributes compared to conventional contrast media products.
 Following a series of government reviews in Japan, the Japanese Ministry of Health and Welfare approved Optiray. The product is expected to be launched this summer in four concentrations, following National Health Insurance (NHI) pricing authorization.
 The X-ray contrast media market in Japan is estimated at $850 million annually at NHI prices, of which low osmolar products account for over 95 percent. In Japan, Optiray will be marketed and distributed under a licensing agreement with Yamanouchi Pharmaceutical Company, Ltd., one of Japan's leading pharmaceutical producers.
 "Introduction of Optiray in Japan is a major step in the continued growth of this product on a global basis," said William J. Mercer, group vice president of medical imaging for Mallinckrodt Medical. "Japan is one of the largest markets in the world for X-ray contrast media, and has one of the highest conversion rates to the new generation agents."
 Mercer said Yamanouchi was selected to distribute Optiray because of that company's large, well-established sales force and because of its strength in the market segments which use contrast agents, particularly the cardiovascular market.
 Optiray was introduced by Mallinckrodt Medical in the Unite States in 1989 -- the first nonionic X-ray contrast medium produced, marketed and distributed by a U.S. company. The product has since been introduced in a number of European countries, including the U.K., Germany and France, as well as in Canada, Australia and Mexico. Optiray also been approved and is awaiting introduction in several other international markets.
 Mallinckrodt Medical, with fiscal 1991 sales of $513 million, is a leading worldwide producer of products used in cardiology, radiology, nuclear medicine, anesthesiology and critical care procedures.
 IMCERA, a Fortune 300 company with fiscal 1991 net sales of more than $1.6 billion, has two other international, technology-based businesses -- Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 -0- 3/27/92
 /CONTACT: Dave Prichard, 708-205-2270, for IMCERA Group/
 (IMA) CO: IMCERA Group Inc. ST: Illinois IN: MTC SU: PDT


CK -- NY028 -- 2317 03/27/92 11:16 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 27, 1992
Words:426
Previous Article:A SPIRITUAL CELEBRATION! HOLLYWOOD ROOSEVELT HOTEL DEDICATES GABLE/LOMBARD SUITE VIA SPECIAL SEANCE SOIREE, MARCH 29
Next Article:THE AMERICAN LEGION REACTS TO ANNOUNCEMENT THAT 140,000 RESERVISTS AND GUARD TROOPS, INCLUDING PERSIAN GULF VETERANS, WILL BE ELIMINATED
Topics:


Related Articles
IMCERA'S MALLINCKRODT MEDICAL UNIT, LIEBEL-FLARSHEIM SIGN AGREEMENT TO MAKE ULTRAJECT PREFILLED SYRINGE COMPATIBLE FOR POWER INJECTORS
FDA ADVISORY PANEL MEETING SCHEDULED FOR ALBUNEX
IMCERA'S MALLINCKRODT MEDICAL UNIT AGREES TO ACQUIRE TRACHEOSTOMY PRODUCTS BUSINESS FROM SORIN BIOMEDICAL, INC.
MBI REPORTS FISCAL YEAR 1993 RESULTS
MBI ANNOUNCES ALBUNEX(R) APPROVAL IN JAPAN
MBI ANNOUNCES LAUNCH OF ALBUNEX(R) IN JAPAN
IMCERA'S MALLINCKRODT MEDICAL UNIT ENTERS CROSS-LICENSE AGREEMENT WITH SCHERING, A.G. GERMANY FOR MRI PATENTS
MALLINCKRODT MEDICAL, OPTIMEDx FORM ALLIANCE TO DEVELOP AND DISTRIBUTE OPTICAL IMAGING AGENTS FOR CANCER CELL DETECTION
MALLINCKRODT INTRODUCES OPTIRAY(R) IN ULTRAJECT(R) SYRINGES IN JAPAN, WORLD'S SECOND LARGEST MEDICAL IMAGING MARKET
EPIX Medical, Mallinckrodt And General Electric Medical Systems Form Groundbreaking Development Collaboration

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters